Comments
Suven Life Sciences Ltd secured two product patents, one each from Mexico and Singapore, corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases.
The granted claims of the patents include the class of selective alpha-4-beta-2 compounds discovered by the Hyderabad-based Suven and are being developed as therapeutic agents for major depressive disorder (MDD).
With these new patents, Suven has a total of 18 granted patents from Mexico and 20 granted patents from Singapore. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II, it said in a release issued here on Friday.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.